Novo Nordisk A/S: Transaction in Own Shares

* Reuters is not responsible for the content in this press release.

Mon Aug 17, 2009 7:00am EDT 

  BAGSVAERD, DENMARK, Aug 17 (MARKET WIRE) -- 
Novo Nordisk A/S - Share repurchase programme

    On 7 August 2009 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

    Under the programme Novo Nordisk will repurchase B shares for an amount
up to DKK 2.4 billion in the period from 10 August 2009 to 18 December
2009.

    Since the announcement as of 7 August 2009, the following transactions
have been made under the programme:




                      Number of    Average       Transaction
                       shares   purchase price  value, DKK
Accumulated, last
announcement                  0                            0
10 August 2009           75,000       305.7500    22,931,250
11 August 2009           75,000       305.4400    22,908,000
12 August 2009           75,000       313.5000    23,512,500
13 August 2009           75,000       317.1900    23,789,250
14 August 2009           75,000       318.0500    23,853,750
Accumulated under the
programme               375,000                  116,994,750

    


Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 71,933 B shares in the period
from 10 August 2009 to 14 August 2009. The shares in these transactions
were not part of the Safe Harbour repurchase programme.

    With the transactions stated above, Novo Nordisk owns a total of
25,255,458 treasury shares, corresponding to 4.1% of the share capital.
The total amount of shares in the company is 620,000,000 including
treasury shares.

    Novo Nordisk is a healthcare company and a world leader in diabetes care.
In addition, Novo Nordisk has a leading position within areas such as
haemostasis management, growth hormone therapy and hormone replacement
therapy. Novo Nordisk manufactures and markets pharmaceutical products
and services that make a significant difference to patients, the medical
profession and society. With headquarters in Denmark, Novo Nordisk
employs more than 27,900 employees in 81 countries, and markets its
products in 179 countries. Novo Nordisk's B shares are listed on the
stock exchanges in Copenhagen and London. Its ADRs are listed on the New
York Stock Exchange under the symbol 'NVO'. For more information,
visit
novonordisk.com.



Further information:

Media:                 Investors:

Outside North America: Outside North America:
Rachel Curtis Gravesen Mads Veggerby Lausten
Tel: (+45) 4442 7603   Tel: (+45) 4443 7919
rcgv@novonordisk.com   mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com

    
Company Announcement no 50 / 2009

    This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.

    Company Announcement no 50 / 2009:
http://hugin.info/2013/R/1335205/317245.pdf

    Copyright Copyright Hugin AS 2009. All rights reserved.

    



Copyright 2009, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.